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Organ-specific regulation of ATP7A 
abundance is coordinated with 
systemic copper homeostasis
Haarin Chun1, Tracy Catterton1, Heejeong Kim3, Jaekwon Lee3 & Byung-Eun Kim1,2
Copper (Cu) is an essential cofactor for various enzymatic activities including mitochondrial electron 
transport, iron mobilization, and peptide hormone maturation. Consequently, Cu dysregulation 
is associated with fatal neonatal disease, liver and cardiac dysfunction, and anemia. While the Cu 
transporter ATP7A plays a major role in both intestinal Cu mobilization to the periphery and prevention 
of Cu over-accumulation, it is unclear how regulation of ATP7A contributes to Cu homeostasis in 
response to systemic Cu fluctuation. Here we show, using Cu-deficient mouse models, that steady-
state levels of ATP7A are lower in peripheral tissues (including the heart, spleen, and liver) under Cu 
deficiency and that subcutaneous administration of Cu to these animals restore normal ATP7A levels 
in these tissues. Strikingly, ATP7A in the intestine is regulated in the opposite manner - low systemic 
Cu increases ATP7A while subcutaneous Cu administration decreases ATP7A suggesting that intestine-
specific non-autonomous regulation of ATP7A abundance may serve as a key homeostatic control for 
Cu export into the circulation. Our results support a systemic model for how a single transporter can be 
inversely regulated in a tissue-specific manner to maintain organismal Cu homeostasis.
Copper (Cu) is an essential trace element required for a vast array of cellular processes in organisms from bac-
teria to humans. Cu serves as a redox-reactive, catalytic cofactor in the enzymatic reactions that drive oxidative 
phosphorylation, iron (Fe) acquisition, protection from oxidative stress, neuropeptide maturation, blood clotting, 
and angiogenesis1–3. However, the ability of Cu to undergo reversible redox changes also makes this element 
deleterious to the organism when present in excess4,5. Because of its dichotomous potential as both an essential 
cofactor and a toxic agent, cells have evolved sophisticated mechanisms for the regulation of Cu acquisition, 
storage, and distribution6,7. As all organismal Cu must pass through the intestine prior to distribution to other 
tissues8,9, cross-talk must take place among tissue types to ensure that import and export of Cu from the intestine 
are coordinated with extraintestinal Cu requirements.
Cu is taken up by intestinal epithelial cells (IECs), routed for incorporation into Cu-dependent proteins, and 
mobilized across the basolateral membrane into peripheral circulation. Ctr1 is a homotrimeric integral mem-
brane protein conserved in eukaryotes ranging from yeast to humans that drives intestinal Cu absorption with 
high affinity and specificity10,11. Once Cu is imported into IECs, the Cu-transporting P-type ATPase known as 
ATP7A conveys it across the basolateral membrane of the enterocyte, where it is delivered into portal circulation. 
The ATP7B Cu exporter, which is structurally related to ATP7A, is expressed in the liver and removes excess Cu 
via transport across the apical membrane into the bile12.
In humans, mutations in the ATP7A gene are known to cause Menkes disease13, which often leads to early 
childhood mortality as a consequence of reduced Cu efflux from enterocytes into the bloodstream14,15. ATP7A is 
normally localized to the trans-Golgi network (TGN)16 where it is essential for the insertion of Cu into important 
secreted enzymes such as tyrosinase17 and lysyl oxidase18. When Cu is abundant, ATP7A-containing vesicles 
traffic to the plasma membrane for Cu efflux16. The Cu-induced trafficking of ATP7A has presumably evolved 
to allow this transporter to shift its function from metallation of secreted cuproenzymes in the TGN to the 
cellular-protective export of excess cellular Cu across the plasma membrane, as well as for absorption of dietary 
Cu by enterocytes in the intestine.
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Figure 1. Elevated Cu increases ATP7A protein levels in cultured cells. (a) IEC-6 cells were exposed to 
basal medium, 100 µM CuCl2 for 3 h, 300 µM BCS for 6 h, or 300 µM BCS plus 100 µM CuCl2 for 6 h. Total 
protein extracts were probed with an anti-ATP7A antibody, anti-CCS, and anti-GAPDH as a loading control. 
A representative immunoblot of seven independent experiments is shown here. (b,c) Relative expression 
levels of ATP7A protein (b) and Atp7a mRNA (c) in IEC-6 cells exposed to CuCl2, BCS, or BCS with CuCl2 
were normalized to basal media conditions from four independent immunoblot and RT-qPCR experiments. 
GAPDH protein and 18S rRNA mRNA, respectively, were used as internal controls in these experiments. Error 
bars indicate mean ± SD of four independent experiments. Means that do not share a letter are significantly 
different (P < 0.05); ns, not significant (P > 0.05) (one-way ANOVA, Tukey’s post hoc test). (d,e) IEC-6 cells 
at ~60% confluence were preincubated with 300 µM BCS-treated medium for 6 h to minimize expression 
levels of ATP7A. Cells were further supplemented with 100 µM CuCl2 for the indicated time (d) or with the 
indicated Cu concentrations for 2 h (e). β-actin and GAPDH levels shown in the lower panel demonstrate 
equal protein loading. Data are representative of two (d) and three (e) independent experiments. (f) IEC-6 
cells were preincubated with 300 μM BCS for 3 h before switching to media containing 200 µM of FeCl3 (Fe), 
ZnCl2 (Zn), MnCl2 (Mn), 10 µM of AgNO3 (Ag), or 10 or 100 μM of CuCl2 (Cu) for 2 h, and 100 μg of protein 
extracts were subjected to immunoblotting. Reduced levels of CCS indicate increased bioavailable Cu levels, 
and GAPDH levels are shown to indicate protein loading of samples. Immunoblots are representative results of 
four independent experiments. (g) Mouse primary liver cells treated with Cu supplementation were analyzed 
by immunoblotting. Mouse liver cells were pretreated for 12 h in BCS-containing medium and then exposed 
to medium containing indicated concentrations of CuCl2 for additional 12 h. GAPDH levels were assayed 
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In contrast to other organisms, systemic Cu fluctuations in mammalian cells do not alter expression of Cu 
homeostasis genes at the transcriptional level7. While it is generally accepted that regulation of mammalian Cu 
homeostasis at the cellular level occurs predominantly via posttranscriptional mechanisms, these mechanisms 
have not yet been shown to play a role in organism-wide systemic Cu homeostasis. In this study, we present evi-
dence that low Cu levels stimulate a reduction in ATP7A protein abundance in tissue culture and in a whole ani-
mal model. Specifically, Cu-deficient mice exhibited substantially reduced ATP7A steady-state protein levels in 
peripheral tissues, including the heart, spleen, and liver, consistent with results from cell culture data. Compared 
to peripheral tissues, however, ATP7A expression in the intestine was inversely regulated in response to Cu levels, 
hinting at a distinct regulatory role for intestinal ATP7A in organismal Cu homeostasis. Our data suggest that this 
intestine-specific regulation of ATP7A protein levels may serve as a key homeostatic mechanism for control of the 
efflux of this essential, yet potentially toxic, trace element into circulation, thus providing new molecular insights 
into how intestinal Cu export is regulated for systemic Cu homeostasis in response to peripheral Cu deficiency.
Results
Elevated Cu increases ATP7A protein levels in cultured cells. To explore Cu-responsive regulation 
of ATP7A, non-polarized rat intestinal epithelial cells (IEC-6) were grown in basal media and treated with CuCl2 
(100 µM), the membrane impermeable Cu (I)-specific chelator bathocuproine disulfonic acid (BCS, 300 µM), or 
300 µM BCS together with 100 µM CuCl2, and analyzed for ATP7A abundance by immunoblotting. A significant 
elevation in ATP7A protein levels was observed in media containing 100 µM Cu, whereas ATP7A levels were 
decreased in BCS-treated cells (Fig. 1a and b). Notably, mRNA levels of Atp7a were not altered by either treatment 
(Fig. 1c). ATP7A levels were enhanced in cells treated simultaneously with BCS and CuCl2 indicating that the 
BCS-induced ATP7A decrease is caused by a Cu-limitation. Increased levels of the Cu chaperone for superoxide 
dismutase (CCS) observed in BCS-treated cells (Fig. 1a) suggested that available cellular Cu was limited, as CCS 
is elevated when Cu is scarce19,20. ATP7A levels in IEC-6 cells were increased in response to 100 µM CuCl2 in a 
time-dependent manner (Fig. 1d), in agreement with a previous report by the Collins group21. Abundance of an 
ectopically-expressed recombinant-tagged (HA-GFP) ATP7A by Cu and BCS was regulated similarly to endog-
enous ATP7A (Fig. S1).
To determine the sensitivity of ATP7A elevation under Cu surplus conditions, IEC-6 cells were pre-grown 
in BCS-treated media for 6 h, washed with phosphate-buffered saline (PBS), and exposed to a range of Cu con-
centrations for 2 h, followed by assessment of ATP7A levels. Cu levels as low as 1 µM were sufficient to enhance 
expression of ATP7A as compared to cells in BCS-treated media, and ATP7A levels progressively increased until 
reaching saturation at treatment with 10 µM of Cu (Fig. 1e), which is within the physiological range of Cu con-
centrations in plasma22.
To test the specificity of ATP7A metal-responsiveness, ATP7A levels were investigated in media containing 
200 µM FeCl3, ZnCl2, MnCl2, or 10 µM AgNO3; exposure to iron, zinc, and manganese at a 2:1 molar excess over 
Cu resulted in no substantial increase in ATP7A protein levels (Fig. 1f). However, ATP7A levels were increased 
by treatment with 10 µM Ag with similar efficiency to equimolar concentrations of Cu. As Ag(I) is isoelectronic 
to Cu(I), these findings suggest that Cu(I), rather than Cu(II), is the primary driver of this process.
To further explore this phenomenon in primary cells, liver cells were isolated from the livers of C57BL/6 mice 
at postnatal day 12 (P12), as liver Cu content and ATP7A expression levels in perinatal mice are higher than those 
in adult mice, suggesting a role for ATP7A in the livers of neonatal mice23–26. Isolated primary liver cells were pre-
treated with BCS overnight and exposed to a range of Cu concentrations. The primary cells treated with as low as 
0.5 µM Cu showed significantly increased ATP7A protein abundance (Fig. 1g) demonstrating that increased cel-
lular Cu levels, as shown by ICP-MS analysis (Fig. 1h), are associated with elevated ATP7A expression. Moreover, 
low micromolar Cu (1 µM) was also sufficient to induce ATP7A expression in human umbilical vein endothelial 
cell (HUVEC) cultures (Fig. 1i). Degradation of the active, glycosylated full-length form of the Ctr1 Cu importer 
(with a concomitant increase in the truncated Ctr1 species) was observed upon Cu treatment, as described previ-
ously in HEK293 cells9. These results demonstrate that cells harbor a mechanism for regulation of ATP7A protein 
levels to adjust the export of Cu in response to exogenous Cu. Although elevation of ATP7A occurs in response to 
Cu media supplementation, it is unclear whether extracellular Cu triggers this process indirectly, or whether Cu 
in the growth media enters cells and elevates intracellular Cu, thereby triggering ATP7A stabilization. In order to 
clarify the mechanism, we investigated the degradation of ATP7A in mouse embryonic fibroblasts (MEF) lacking 
the high-affinity Cu importer Ctr1 (Ctr1−/−)27, along with Ctr1+/+ wild type cells, and Ctr1−/− cells transfected 
as a loading control. Immunoblots are representative results of four independent experiments. (h) Total Cu 
levels in mouse primary liver cells were measured by ICP-MS upon supplementation with 100 µM BCS or the 
indicated Cu concentrations. Data are presented as mean ± SD from four biological replicates. Values with 
one different letter are significantly different from each other (P < 0.05) (One-way ANOVA, Tukey’s post hoc 
test). (i) Immunoblotting of ATP7A and Ctr1 levels in HUVEC cells treated with a range of concentrations of 
CuCl2 for 12 h. The arrowheads labeled g and t indicate the full-length glycosylated monomer and the amino-
terminal truncation forms of Ctr1, respectively. The glycosylated and truncated form of Ctr1 have previously 
been demonstrated to represent mature glycosylated Ctr1 species, and amino-terminal cleaved truncated Ctr1, 
respectively33. Data are representative of three independent experiments. (j) ATP7A protein levels in Ctr1+/+ 
and Ctr1−/− MEFs. Total protein extracts isolated from wild type (Ctr1+/+) MEFs, Ctr1−/− MEFs transfected 
with empty vector (vec) exposed to basal media or 100 μM CuCl2 for overnight (vec + Cu), and Ctr1−/− MEFs 
transfected with a plasmid expressing Ctr1 were resolved by SDS-PAGE and analyzed by immunoblotting. Data are 
representative for three independent experiments. Full-length blots are presented in Supplementary Figure 11.
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with a wild type Ctr1-expressing plasmid, grown in Cu-supplemented media. ATP7A protein levels in Ctr1−/− 
MEF cells transfected with vector plasmid were lower than those in Ctr1+/+ MEFs and Ctr1−/− MEFs treated with 
exogenous Cu (Fig. 1j), indicating that the intracellular Cu pool modulates ATP7A abundance.
Post-translational control of ATP7A abundance in response to Cu. A previous report showing no 
changes in  Atp7a mRNA levels in response to supplemental Cu in rat IECs21 suggests steady-state ATP7A protein 
levels are regulated post-transcriptionally. ATP7A is very stable protein, with a reported half-life of over 40 h in 
a variety of cells21,28–30. To further explore Cu-dependent ATP7A regulation, IEC-6 cells were treated with Cu or 
BCS in the presence of the translation inhibitor cycloheximide (CHX), and steady-state levels of ATP7A were 
analyzed by immunoblotting over time. In IEC-6 cells, elevated steady-state levels of ATP7A by Cu treatment 
were significantly diminished within an hour of exposure to 300 µM BCS; no reduction in ATP7A was observed 
under Cu-excess conditions upon 100 µM Cu treatment (Fig. 2a).
To test whether this enhanced turnover of ATP7A occurs through the proteasome pathway, IEC-6 cells pre-
treated with Cu were exposed to BCS along with the proteasome inhibitors MG132 and bortezomib, alone or in 
combination. These proteasome inhibitors partially abrogated the decrease in steady-state levels of ATP7A pro-
tein in response to cellular Cu deprivation (Fig. 2b), suggesting that the reduction in ATP7A protein levels was 
due, at least in part, to increased proteolysis via a proteasomal pathway.
A liver-specific role for active Cu sequestration. To test the physiological significance of Cu-responsive 
ATP7A abundance regulation, C57BL/6 mice were subcutaneously (SQ) administered Cu or saline9 at P7 for 
three consecutive days. Mice were dissected at P10 and assayed for Cu accumulation in tissues by ICP-MS. 
While no marked Cu accumulation was observed in the serum or the heart, the liver showed highly elevated Cu 
Figure 2. Cu-deficiency stimulates the degradation of ATP7A protein. (a) IEC-6 cells pretreated with media 
containing 100 μM CuCl2 for 2.5 h were further treated with 50 μg/mL cycloheximide (CHX). Following 30 
min incubation, cells were exposed to fresh culture media containing 300 μM BCS and 50 μg/ml CHX and then 
lysed after 0.5, 1, 3, or 6 h (lanes 3–6). Whole cell lysates were processed for immunoblotting analysis using 
antibodies as indicated. Immunoblot images are representative results of four independent experiments. (b) 
IEC-6 cells were pretreated with media containing 100 μM CuCl2 for 1 h before addition of 20 μM MG132, 100 
nM bortezomib, or DMSO (vehicle control) and treated for another 90 min. Cells were further treated with 
50 μg/mL CHX for 30 min, and then the media was replaced with fresh media containing 300 μM BCS and 
50 μg/mL CHX for 2 h in the presence of MG132 and/or bortezomib, or DMSO. Na+/K+-ATPase served as a 
loading control. Representative immunoblots of four independent experiments are shown. Full-length blots are 
presented in Supplementary Figure 12.
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accumulation in a dose-dependent manner (Fig. 3a–c). As metallothionein (MT) genes are induced by high Cu 
exposure31, mRNA levels of Mt-1 and Mt-2 genes were assessed to explore whether these correlate with hepatic 
Cu accumulation. As expected, while expression of Mt-1 was modestly increased only in mice administered Cu 
at the concentration of 10 μg/g BW, Mt-2 gene was significantly elevated in mice administered SQ Cu compared 
to control mice (Fig. 3d and e). Hepatic ATP7A expression was enhanced only in mice administered Cu at the 
concentration of 10 μg/g total body weight (BW) (Fig. 3g and S2a). Elevated serum Cu levels were also detected 
only in mice treated with 10 μg Cu/g BW (Fig. 3a), suggesting that this level of Cu exceeds the capacity of the liver 
to excrete surplus Cu.
As the Cu-specific importer Ctr1 is inactivated through endocytosis and degradation in cultured cells in 
response to Cu treatment (Fig. 1i)32, and the mature glycosylated form of Ctr1 was increased in the intestines and 
hearts of wild type mice fed a Cu-deficient diet33, we performed immunoblot analysis of Ctr1 protein levels in 
the livers of mice administered with Cu. Unexpectedly, whereas mRNA levels of Ctr1 were not changed (Fig. 3f), 
the glycosylated full-length form of Ctr1 protein was strongly elevated in the livers of Cu-treated mice, with a 
concomitant increase in hepatic Cu accumulation and a reduction in CCS levels, in a dose-dependent manner 
Figure 3. Ctr1 protein levels and Cu accumulation in the liver are elevated by subcutaneous Cu administration. 
(a–c) Cu levels measured by ICP-MS in serum (a), heart (b), and liver (c) from C57BL/6 mice (P10) SQ 
administered indicated amounts of Cu-histidine for three consecutive days beginning at P7. Data (means ± SD) 
are from seven to nine mice of each condition (n = 2–5 mice for males and females per Cu dose), and means 
marked with different letter superscripts are significantly different at p = 0.05 (one-way ANOVA, Tukey’s post 
hoc test). (d–f) Quantitative RT-qPCR analysis of mRNA levels of Mt1, Mt2, and Ctr1. Levels of Mt1 (d), 
Mt2 (e), Ctr1 (f) transcripts were measured relative to Gapdh mRNA levels in the livers of individual mice at 
P10 (male, n = 2; female, n = 2) for each condition, which were SQ administered Cu or saline at P7 for three 
consecutive days. Bars indicate mean ± SD for each condition. Means that do not share a letter are significantly 
different (P < 0.05). ns, not significant (P > 0.05) (one-way ANOVA, Tukey’s post hoc test). (g and h)  
Immunoblot analysis of ATP7A, Ctr1, CCS, and GAPDH in liver (g) and heart (h) extracts from two 
representative mice administered saline or indicated amounts of Cu-histidine per body weight (µg/g) for three 
consecutive days beginning at P7. The arrowheads indicate the glycosylated full-length (g) and truncated form 
(t) of Ctr1, respectively. GAPDH levels were assayed as a loading control. Results are representative of three to 
four independent experiments performed on a total of male (liver, n = 5, 4, 4, and 6; heart, n = 5, 3, 5 and 6) and 
female mice (liver, n = 6, 4, 4, and 5; heart, n = 6, 4, 2, and 5), which were SQ administered with 0, 1.5, 5, and 10 
µg CuCl2–histidine per body weight (g). Full-length blots are presented in Supplementary Figure 13.
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Figure 4. Systemic Cu status differentially regulates ATP7A protein levels in enterocytes and peripheral 
tissues. (a) Relative Cu levels in liver extracts, serum, intestinal epithelial cells (IEC), and total brain extracts 
of control mice (Ctr1flox/flox or Ctr1flox/+) and Ctr1int/int mice SQ administered saline or 10 µg of Cu-histidine 
per body weight (g) at P10, normalized to those of control (Ctr1flox/flox or Ctr1flox/+) mice administered saline. 
Data are shown as relative fold change compared with control (means ± SD) from seven to nine mice per 
condition (n = 2–5 mice per sex per condition), and means followed indicated with different letter superscripts 
are significantly different at p = 0.05 (two-way ANOVA, Tukey’s post hoc test). (b,e,f and g) Representative 
Ctr1flox/flox and Ctr1int/int mice littermates SQ administered saline or Cu-histidine at P10 and sacrificed at P12 for 
analysis. Protein extracts from the indicated tissues from these mice were immunoblotted with anti-ATP7A, 
anti-CCS, anti-ATP7B, anti-Ctr1, and anti-GAPDH antibodies. The arrowheads labeled g and t indicate the 
full-length glycosylated and truncated forms of Ctr1, respectively. Data shown here are representative of three to 
eleven independent experiments performed for each mouse tissue (liver, n = 12, 10, 12, and 10; heart, n = 6, 6, 4, 
www.nature.com/scientificreports/
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(Fig. 3c,g and S2). However, peripheral tissues such as the heart, spleen and brain showed no obvious changes in 
protein abundances of Ctr1 and ATP7A (Fig. 3h and S3). These data suggest that Cu-responsive elevation of the 
mature glycosylated Ctr1 protein is liver-specific, suggesting a mechanism by which Cu can be sequestered in the 
liver under Cu-excess conditions. Taken together, these findings suggest the existence of a liver-specific role for 
Ctr1 in active Cu detoxification for systemic Cu homeostasis.
Organ-specific regulation of ATP7A abundance. The administration of Cu treatment in C57BL/6 mice 
did not lead to robust changes in Cu levels in the circulation (Fig. 3a) and resulted in an increase in ATP7A levels 
in the liver only in mice administered Cu at the concentration of 10 μg/g BW (Fig. 3g and S2a) compared to those 
in cell culture models (Fig. 1g) despite comparable cellular Cu levels between the in vitro (Fig. 1h) and in vivo 
(Fig. 3c) experimental conditions. We therefore postulated that the tissues of Cu-deficient mice may be more 
sensitive to Cu fluctuations in circulation than those from Cu-adequate wild-type mice. To test this hypothesis, 
we utilized the intestine-specific Ctr1 knockout mouse (Ctr1int/int) as a Cu-deficient animal model. Ctr1 knockout 
in the intestine markedly reduces Cu accumulation in peripheral tissues including the liver, heart, and spleen, 
and results in severe Cu deficiency phenotypes at P10 9,33. P10 Ctr1int/int mice were SQ administered 10 μg Cu/g 
BW and sacrificed after 48 h, and the steady-state levels of Cu in several peripheral tissues of Ctr1int/int and control 
mice (Ctr1flox/flox) administered with Cu or saline were evaluated by ICP-MS. As shown in Fig. 4a, Ctr1int/int mice 
demonstrated significantly reduced Cu accumulation in all peripheral tissues tested. Consistent with previous 
data, the intestine of Ctr1int/int mice hyperaccumulated Cu in a non-bioavailable pool9, as supported by elevated 
CCS abundance representing reduced bioavailable Cu levels (Fig. 4g and i).
To explore whether fluctuations in Cu concentrations in peripheral tissues are associated with changes in 
ATP7A protein expression levels, we examined ATP7A levels from Ctr1int/int and Ctr1flox/flox pups administered 
with Cu or saline injections. ATP7A levels in the peripheral tissues (such as the livers) of Ctr1int/int mice were 
clearly decreased as compared to those in age-matched sibling control mice (Ctr1flox/flox); however, this decrease in 
ATP7A levels was rescued to the levels found in control Ctr1flox/flox mice by SQ Cu administration (Fig. 4b and c). 
Hyper-accumulated Fe levels in the intestine and liver, likely due to a reduction of Fe efflux facilitated by the 
Cu-dependent ferroxidase hephaestin and ceruloplasmin9, were also rescued by Cu administrations in these mice 
(Fig. S4). The abundance of hepatic ATP7B protein was not changed by Cu injection or Cu deficiency (Fig. 4b), 
which is consistent with observations that elevated Cu levels in the body alters the cellular localization of ATP7B 
from the TGN to lysosomes without any concomitant change in ATP7B protein levels34.
While Cu deficiency did not affect Ctr1 abundance in the livers of Ctr1int/int mice, the glycosylated full-length 
form of hepatic Ctr1 was highly expressed in both Cu-treated Ctr1int/int and Ctr1flox/flox mice as compared to 
saline-treated Ctr1int/int and Ctr1flox/flox mice (Fig. 4b and S5), reaffirming that the liver acts as a Cu storage and 
sequestration organ under Cu overload conditions. Increased CCS in the livers of Ctr1int/int pups due to Cu defi-
ciency was suppressed by Cu administration, (Fig. 4b and d), consistent with the ICP-MS analysis (Fig. 4a). 
ATP7A levels in several other peripheral tissues including the hearts and spleens similarly exhibited reduced 
ATP7A levels in Ctr1int/int mice as compared to Ctr1flox/flox mice, and these levels were restored by Cu adminis-
tration (Fig. 4e,f and S6a–d). These in vivo findings suggest that ATP7A protein abundance in several peripheral 
organs is regulated in response to Cu levels in animals.
Intestinal ATP7A protein abundance primarily responds to systemic Cu status. Since intesti-
nal Cu absorption is the primary point at which Cu transport into circulation can be regulated, we examined 
the expression levels of ATP7A in intestinal enterocytes in Ctr1- and Cu-deficient mice. Interestingly, intestinal 
ATP7A abundance was inversely correlated with bioavailable Cu, in direct opposition to its regulation in the liver 
(Fig. 4b,c,g and h). While bioavailable Cu was limited in the intestinal epithelial cells, as indicated by increased 
levels of CCS (Fig. 4g and i), ATP7A expression was strongly elevated as compared to that in saline-treated 
Ctr1flox/flox mice; this elevated ATP7A was suppressed by Cu administration, leading to increases in bioavailable 
Cu in the intestine and other tissues as compared to that in saline-treated Ctr1int/int mice (Fig. 4g,h and i). Elevated 
intestinal CCS protein levels in Ctr1int/int mice were rescued by Cu-administration, indicating that bioavailable Cu 
was increased in the enterocytes in Ctr1int/int mice administered with Cu (Fig. 4a,g and i)2,9,35. This result was not 
anticipated, as our Ctr1−/− MEFs results (Fig. 1j) indicate that bioavailable Cu levels in enterocytes are severely 
limited, which would lead to decreased ATP7A levels. Enterocytes displayed the opposite response when com-
pared to that of cultured cells and peripheral tissues. These intriguing observations suggest that while ATP7A 
acts to manage intracellular Cu homeostasis in peripheral tissues, intestinal ATP7A levels are at least partially 
determined by extraintestinal Cu status.
and 4; spleen, n = 6, 4, 9, and 4; enterocytes, n = 22, 20, 22, and 22). (c,d,h and i) Quantification of ATP7A and 
CCS expression in Ctr1flox/flox and Ctr1int/int mice administered with saline or Cu. Relative protein abundances 
of hepatic and intestinal ATP7A (c and h) and CCS (d and i) were quantified by analyzing immunoblots of 
10-22 mice tissues (liver, n = 12, 10, 12, and 10; enterocytes, n = 22, 20, 22, and 22) for each condition for 
statistical analysis. Error bars represent average ± SD, and means indicated with different letters are significantly 
different from each other at p = 0.05 (Two-way ANOVA, Tukey’s post hoc test). (j) Cu-responsiveness of 
isolated Ctr1int/int enterocytes cultures. Isolated enterocytes from Ctr1flox/flox and Ctr1int/int mice were cultured 
in medium containing 100 μM CuCl2 or 300 μM BCS for 2 h. Total protein extracts of cultured enterocytes 
were subjected to SDS-PAGE and analyzed by immunoblotting. Immunoblots shown here are representative 
of three independent experiments performed on a total of n = 5, 5, 7, and 7. Full-length blots are presented in 
Supplementary Figure 14.
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To further explore the in vivo regulation of ATP7A abundance under differential Cu availability, Atp7a mRNA 
levels in mouse tissues were measured by reverse transcription quantitative PCR (RT-qPCR). Atp7a steady-state 
mRNA levels did not significantly change in either the livers or the intestines of Ctr1int/int and Ctr1flox/flox mice 
administered Cu or saline (Fig. S7). This indicated that control of ATP7A abundance in response to Cu occurs 
post-transcriptionally, similar to regulation in cell cultures (Fig. 1a–c) and reminiscent of the dramatic changes 
in ATP7A protein, but not mRNA, in the intestine caused by cardiac-specific loss of Ctr1 in mice (Ctr1hrt/hrt)25 
(Fig. S8). Taken together, these results demonstrate that intestinal epithelial cells control ATP7A protein abun-
dance via post-transcriptional regulation in response to peripheral tissue Cu deficiency.
The diametrically opposing effects of Cu deficiency on ATP7A expression in peripheral tissues compared 
to enterocytes raises the question as to what mechanism underlies communication between the intestine and 
Cu-deficient peripheral tissues. Isolated enterocytes from Ctr1int/int and Ctr1flox/flox mice were exposed to culture 
medium treated with Cu or BCS for 2 h. Immunoblot analysis of these cells revealed that elevated intestinal 
ATP7A in Ctr1int/int mice was decreased by BCS treatment, concomitant with an increase in CCS expression in 
isolated and cultured enterocytes when compared to those from the Cu-treated medium (Fig. 4j, S6e and S6f). 
Thus, when isolated in culture, enterocytes appear to regulate ATP7A expression in response to Cu availability 
in a manner that more closely resembles that of peripheral tissues and cultured cells than that found in entero-
cytes in their native milieu. Cu treatments of either the apical or basolateral side of polarized IEC-6 cells using 
a trans-well system led to elevation of ATP7A levels (Fig. S9) suggesting polarization per se is not sufficient to 
recapitulate the ATP7A phenotype shown in the intestine of Cu-injected Ctr1int/int (Fig. 4g).
To determine whether the changes in intestinal ATP7A abundance could be dependent upon other cell types 
found in the intestine, we examined the localization of ATP7A across the duodenum and upper jejunum of Ctr1int/int  
and Ctr1flox/flox mice. Multi-label confocal immunofluorescence microscopy showed that ATP7A expression was 
specific to enterocytes at the villus tip in the intestine (Fig. S10a–c). The majority of ATP7A was appeared in 
intracellular puncta in both Ctr1int/int and Ctr1flox/flox mice, with partial localization in the basolateral membranes 
Figure 5.  Dietary Cu-deficient mice exhibit elevated protein levels of ATP7A and Ctr1 in the intestine. (a and d) 
Immunoblot analysis of ATP7A and CCS in the liver (a) and enterocytes (d) of three representative mice (P15) fed 
a control or Cu-deficient diet. GAPDH levels were assayed as a loading control. The arrowheads labeled g and t 
indicate the glycosylated full-length and truncated forms of Ctr1, respectively. Data shown in here are representative 
of three independent experiments performed on male (n = 3 and 3) and female (n = 3 and 4) mice for Cu-adequate 
and Cu-deficient conditions. (b,c,e,f,g and h) Quantification of ATP7A, CCS, and Ctr1 expression in the liver and 
enterocytes of Cu-adequate (CuA; male, n = 3; female, n = 3) or Cu-deficient (CuD; male, n = 3; female, n = 4) 
mice. Error bars indicate mean ± SD. Statistics: two-tailed unpaired Student’s t-test (ns, P > 0.05, **P < 0.01, and 
***P < 0.001). Full-length blots are presented in Supplementary Figure 15.
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(marked by the Na+/K+-ATPase) (Fig. S10d and e). Highly elevated levels of ATP7A were apparent in Ctr1int/int 
mice as compared to control mice, confirming the immunoblot data (Fig. 4g and h). Taken together, these find-
ings indicate that highly increased intestinal ATP7A in Ctr1int/int mice primarily localizes to intracellular vesicles 
in the enterocytes of intestinal villi, a distribution similar to that in Ctr1flox/flox mice.
The results from the Ctr1int/int mice support the hypothesis that ATP7A expression in the enterocyte is con-
trolled by the need to supply Cu to peripheral tissues. Alternatively, the changes to ATP7A abundance in the 
intestine could also be attributed to the intestinal loss of Ctr1 in Ctr1int/int mice, independent of peripheral Cu 
deficiency. To separate these two possibilities, we determined if intestinal ATP7A expression was regulated by 
Cu deficiency in wild-type mice in a similar manner to their Ctr1int/int and Crt1hrt/hrt counterparts. We performed 
analysis of ATP7A levels in mice fed Cu-adequate and Cu-deficient diets. Dietary Cu-deficiency in wild type 
mice correlated to a reduction in hepatic ATP7A expression in parallel with increased CCS expression result-
ing from Cu restriction (Fig. 5a–c). However, abundance of the intestinal ATP7A Cu efflux pump was signifi-
cantly enhanced, even while enterocytes demonstrated severe Cu-deficiency, as indicated by elevated levels of 
CCS (Fig. 5d–f), similar to the observations from Ctr1int/int mice, demonstrating that increased ATP7A abundance 
in the intestine is dependent on peripheral Cu deficiency and not on intestinal loss of Ctr1. Moreover, entero-
cytes expressed higher amounts of the glycosylated full-length form of Ctr1 in the intestinal epithelial cells of 
Cu-deprived mice (Fig. 5d,g and h) suggesting the mechanism for Cu-deficiency induced stabilization of Ctr1 
is conserved in the enterocytes as observed in cell-culture models. Together, these findings suggest an intestinal 
regulatory mechanism for dietary Cu absorption via increased expression of the Ctr1 Cu importer and ATP7A 
Cu exporter in wild type mice, and indicate that intestinal ATP7A regulation is distinct from that in the liver and 
other peripheral organs.
Discussion
The unique physiological functions and specific cell types found in various mammalian organ systems result in 
differential demands for Cu. The role of the Cu exporter ATP7A in cellular Cu delivery to secretory pathways 
and into peripheral circulation in organisms has been well established via its Cu-responsive trafficking7,16,36–38. 
However, the mechanisms by which ATP7A abundance in distinct tissues responds to changes in organismal Cu 
remain poorly understood2,13,25. Here we present data that suggest ATP7A abundance is an important regula-
tory point for Cu homeostasis in peripheral tissues including the heart and spleen; in mice, excess Cu results in 
increased ATP7A protein levels in liver tissue, consistent with a need to prevent over-accumulation of this metal 
through enhanced ATP7A-driven Cu export. Our data demonstrate that in response to potentially detrimental 
Cu concentrations, cell systems not only relocate ATP7A to post-Golgi vesicles and the plasma membrane16, but 
also increase the protein abundance of ATP7A in order to enhance export of Cu from cells and restore intracel-
lular Cu homeostasis (Fig. 1 and 2)21. Conversely, under Cu deficiency, our results suggest that ATP7A protein 
abundance is reduced, at least in part, by the proteasome system (Fig. 2b), consistent with a reduced need to 
export Cu from the cell. It is worth noting that Cu status regulates the multicopper oxidase hephaestin via a 
proteasome-mediated pathway39, and that XIAP targets CCS for ubiquitination through its E3 ubiquitin ligase 
activity, resulting in the degradation of CCS under adequate levels of Cu40. It is possible that a similarly-regulated 
E3 ubiquitin ligase binds to ATP7A and targets it for degradation during Cu deficiency.
While it is known that the liver is a major Cu storage organ in mammals, little attention has been paid to the 
delineation of the biochemical mechanisms by which mammals regulate the detoxification, storage, and mobi-
lization of Cu41. We observed that Cu accumulation is drastically increased in the liver as compared to other 
peripheral tissues in mice administered SQ Cu (Fig. 3c and 4a), supporting the concept of the liver as the principle 
Cu storage organ. Ctr1 is known to be internalized and degraded in response to high Cu levels in cultured cells32, 
which we also observed in this study (Fig. 1i). Unexpectedly, the liver demonstrated an increase in the mature 
glycosylated form of Ctr1 in response to Cu administration when compared to levels in mice administered saline 
(Fig. 3g and 4b). This finding suggests that in contrast to other tissues, liver Ctr1 expression is elevated under 
high Cu conditions; this is possibly to facilitate removal of Cu from the circulation and prevent build up in other 
Cu-susceptible peripheral tissues. As such, it is plausible that the responsiveness of Ctr1 in the liver in vivo is dif-
ferent from that in cell culture because organismal Cu homeostasis is coordinated by multiple layers of regulation, 
and likely influenced by one or more additional Cu-dependent circulatory factor(s) rather than changes in Cu 
concentrations alone. The increased hepatic ATP7A protein may function to export Cu in response to Cu over-
load when Cu exceeds the capacity of the liver as suggested in cell culture studies (Fig. 1). An alternate possibility 
would be that ATP7A is upregulated to maintain uninterrupted Cu supply to secretory pathways for Cu depend-
ent enzymes, while ATP7B traffics to the apical membrane to excrete surplus Cu in the liver. The mechanisms 
underlying the contrasting responses of Ctr1 in liver versus other tissues remain to be determined.
Unexpected observations from our analyses of Cu-deficient mice include the elevated protein levels of ATP7A 
and glycosylated full-length form of Ctr1 in enterocytes associated with limited levels of bioavailable intracellu-
lar Cu, while under these same conditions, peripheral tissues showed significantly diminished ATP7A expres-
sion. Additionally, while Cu accumulation was significantly increased in the enterocytes of Ctr1int/int mice, SQ Cu 
administration into these mutant mice suppressed intestinal ATP7A expression and increased Ctr1 truncation, 
which would limit dietary Cu import by the reduced Cu transport activity (Fig. 4a,g,h and S5)42,43. A previous 
study revealed that cardiac-specific Ctr1 ablation in mice (Ctr1hrt/hrt) results in a dramatic upregulation of ATP7A 
expression in both the intestine and liver and a concomitant elevation of serum Cu levels25. Our results raise the 
possibility that modulation of ATP7A abundance in the intestine, not the liver, is the principal means by which 
Cu supply to circulation is regulated depending upon Cu demands from peripheral tissues. Generation and anal-
ysis of liver-specific ATP7A knockout mice could delineate the role of ATP7A and physiological significance of 
its abundance regulation in the liver. Notably, changes in Cu levels did not significantly alter the subcellular dis-
tribution of ATP7A in enterocytes (Fig. S10). This strengthens the possibility that in vivo, the intestine increases 
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ATP7A abundance in intracellular vesicles to efflux Cu via exocytosis through basolateral membrane into circu-
lation as proposed by others36.
Intestinal epithelial cells in Ctr1int/int mice administered with SQ Cu exhibited profound Cu accumu-
lation in parallel with enhanced levels of bioavailable Cu as indicated by decreased CCS, and a rescued Fe 
hyper-accumulation phenotype when compared with control (saline-administered) Ctr1int/int mice (Fig. 4a,g,i 
and S4). Given that Ctr1 localizes to the apical membrane in enterocytes33, and intestinal Ctr1 is poorly expressed 
in Ctr1int/int mice9, these observations suggest the existence of alternative Cu uptake machinery at the basolateral 
membrane of intestinal epithelial cells. Such a mechanism may have its origins in utero where Cu delivery to 
enterocytes might occur via Ctr1-independent serosal-to-mucosal Cu transport. A possible pathway in this pro-
cess might be an anion exchanger-dependent Cu import system44, which remains to be identified.
Studies of cultures of isolated enterocytes from Ctr1int/int mice presented here show that elevated ATP7A 
expression in the enterocytes of Cu-deficient mice is suppressed in culture with BCS-treated medium (Fig. 4j), 
whereas identical enterocytes showed stronger ATP7A expression concomitant with reduced serum Cu levels as 
compared to Ctr1flox/flox mice (Fig. 4g). These observations underscore the importance of the intestine as a regula-
tor of Cu entry to the body, which must respond not only to intrinsic Cu needs, but those of peripheral tissues via 
the basolateral side of epithelial cells that is thought to be in direct communication with circulating effectors. As 
intestinal ATP7A levels in both Ctr1int/int (low serum Cu)9, and Ctr1hrt/hrt (high serum Cu)25 mice are elevated, the 
data suggest that serum Cu itself is not a direct intestinal ATP7A inducer. Instead, we speculate that a circulating 
factor likely regulates intestinal levels of ATP7A. Clearly, more extensive studies are required to identify such a 
molecule and its mode of action. Such studies will greatly expand our understanding of the regulation of systemic 
Cu homeostasis and human diseases caused by Cu dysregulation.
Methods
Antibodies. The anti-ATP7A antibody (generous gift from Drs. Stephen G. Kaler, National Institutes of 
Health (NIH), Bethesda, MD and Michael J. Petris, University of Missouri, Columbia, MO), anti-ATP7B anti-
body (generous gift from Dr. Svetlana Lutsenko, Johns Hopkins University, Baltimore, MD), anti-Ctr1 anti-
body9, anti-β-tubulin antibody (Cell Signaling Technology), anti-β-actin antibody (Sigma), and anti-Na+/
K+-ATPase (Thermo Scientific) antibody were each used at a 1:1,000 dilution. The anti-CCS antibody (Santa 
Cruz Biotechnology) and anti-GAPDH antibody (Sigma) were used at a 1:400 dilution and 1:10,000 dilution, 
respectively. Horseradish peroxidase-conjugated anti-rabbit or anti-mouse IgG (Rockland Immunochemicals) 
were used as the secondary antibody for immunoblotting at a 1:5,000 dilution. Immunoblots were detected 
using SuperSignal West Pico or Femto Chemiluminescent Substrate reagents (Thermo Fisher Scientific) using 
a chemidocumentation imaging system (Bio-Rad). The anti-Na+/K+-ATPase antibody was purchased from 
the Developmental Studies Hybridoma Bank (DSHB) for immunofluorescence experiments. Alexa Fluor 488 
anti-rabbit IgG, Alexa Fluor 568 anti-mouse IgG, Alexa Fluor 647 WGA-conjugate, and ProLong Gold Antifade 
mounting reagent with DAPI were obtained from Life Technologies.
Cell Culture. Rat intestinal epithelial cells (IEC-6) and HUVEC cells were obtained from the American Type 
Culture Collection (ATCC) and cultured according to the distributor’s recommendations. Wild-type (Ctr1+/+) 
and Ctr1−/− MEFs were cultured in Dulbecco’s Modified Eagle Medium (DMEM; Lonza) supplemented with 10% 
(v/v) heat-inactivated fetal bovine serum (FBS; Atlanta Biologicals), 1 × MEM non-essential amino acids (Lonza), 
50 µg/mL uridine, 100 U/mL penicillin/streptomycin (Lonza), and 55 µM 2-mercaptoethanol. All cells were cul-
tured under 5% CO2 at 37 °C. Cells at ~60% confluence were collected and washed three times with ice-cold 
PBS (pH 7.4). CuCl2 (Alfa Aesar) and bathocuproinedisulfonic acid Cu chelator (BCS; Acros) were used for Cu 
level-responsive ATP7A expression change experiments with various cell lines. For proteasomal degradation 
inhibition experiments, IEC-6 cells were treated with 50 μg/mL cycloheximide (CHX; Sigma), 20 μM MG-132 
(Sigma), and 100 nM bortezomib (ApexBio). Cell pellets were suspended in ice-cold cell lysis buffer (PBS pH 7.4, 
1% Triton X-100, 0.1% sodium dodecyl sulfate (SDS), 1 mM EDTA) containing Halt protease inhibitor cocktail 
(Thermo Scientific), briefly vortexed, and incubated for 1 h. Cell suspensions were centrifuged at 16,000 xg at 4 °C 
for 15 min to remove insoluble material, and supernatants were collected. Protein concentrations were measured 
using the BCA Protein Assay Kit (Thermo Scientific). The indicated amount of protein extract was fractionated 
by SDS-gel electrophoresis on 4-20% gradient gels (Bio-Rad) and immunoblotted.
IEC-6 cells were grown on 24-mm polyester membrane transwells with 0.4-μm pores (Corning) until conflu-
ent. When cultures reach to 90% confluence, the growth medium was exchanged every day to produce a polarized 
cell monolayer. Formation of tight junctions was monitored by the measurement of trans epithelial electrical 
resistance (TEER) using an EVOM2 meter and STX2 electrodes (World Precision Instruments). Cells were 
judged to be ready for Cu uptake experiments when the TEER value was ~400 Ω × cm2. After incubating cells 
with 200 μM BCS for 24 h, both compartments were filled with fresh culture medium containing BCS, CuCl2, or 
10 mM EDTA for 12 h. Cells were rinsed with ice-cold PBS (pH 7.4), scraped in the same ice-cold lysis buffer to 
harvest, and analyzed by immunoblotting.
Primary liver cells were isolated from mice at P12 according to the procedure previously described in detail45. 
Briefly, an incision was made on the right atrium with scissors to ensure a route for overflow, then perfusion was 
performed with calcium-free Hanks’ balanced salt solution (HBSS; Lonza) supplemented with 0.5 mM EDTA 
(Sigma) at 37 °C at a rate of 3.5 mL/min, followed by HBSS supplemented with 0.3 mg/mL collagenase (Sigma) 
and 5 mM CaCl2 under the same conditions at a rate of 5 mL/min. The total-collected liver cell suspension was 
then filtered through a 100-µm nylon mesh and centrifuged at 50 × g for 5 min. Next, the pellet was resuspended 
and incubated in DMEM with 10% FBS, 0.1 µM insulin (Sigma), and 100 U/mL penicillin/streptomycin. After 3 h 
of incubation at 37 °C in an atmosphere of 5% CO2, the medium was changed to M199 supplemented with 0.1 µM 
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dexamethasone, 0.1 µM 3,3′,5-triiodo-L-thyronine, 0.1 µM insulin, and 100 U/mL penicillin/streptomycin and 
incubated for further analysis.
Animal and Tissue Preparations. For the Cu administration experiment, pups at P7 (C57BL/6J, Jackson 
Laboratory) were SQ administered 50 μL of saline containing 10 μg CuCl2 with 19.12 μg L-histidine/g mouse BW 
or 50 μL of saline alone for 3 consecutive days and sacrificed at P10. The intestinal Ctr1 knockout mice (Ctr1int/int) 
and control mice (Ctr1flox/flox and Ctr1flox/+) were generated as described previously9. Ctr1flox/flox and Ctr1int/int mice 
pups were administered the same amount of Cu-histidine or saline alone given subcutaneously at P10 and dis-
sected two days later (P12). To generate dietary Cu-deficient mice, dietary treatment of dams began on embryonic 
day 16 or 17, as previously described8. Dams from wild type mice were fed Cu-deficient or Cu-adequate diets, 
consisting of a Cu-deficient purified diet (TD.80388, Envigo) and either sterilized distilled low-Cu drinking water 
or Cu-supplemented drinking water (20 μg CuCl2/mL), respectively. Pups were sacrificed at P15 due to clear evi-
dence of severe Cu deficiency. All procedures involving animals were carried out in accordance with the National 
Institutes of Health Guide for the Care and Use of Laboratory Animals and have been approved by the Institutional 
Animal Care and Use Committee at the University of Maryland, College Park (protocol number R-15-14). Tissues 
were dissected following washing with ice-cold PBS, frozen in liquid nitrogen, and stored at −80 °C until use. For 
the isolation of intestinal epithelial cells, the small intestine was opened along the long axis, washed in ice-cold 
PBS, and soaked in PBS containing 1.5 mM EDTA and protease inhibitors at 4 °C for 30 min with gentle agita-
tion46. After incubation, the mesenchymal layer was removed, and intestinal epithelial cells were washed three 
times with ice-cold PBS with protease inhibitors and recovered by centrifugation at 2000 × g for 3 min.
Dissected tissues or purified intestinal epithelial cells were homogenized in ice-cold cell lysis buffer (PBS pH 
7.4, 1% Triton X-100, 0.1% SDS, 1 mM EDTA) containing Halt protease inhibitor cocktail (Thermo Scientific) in 
1.5 mL centrifuge tubes by pellet mixer (VWR) on ice. Homogenates were incubated on ice for 1 h followed by 
centrifugation at 16,000 × g for 15 min at 4 °C. The supernatants were used as total extracts for immunoblotting. 
Protein concentrations were measured using the BCA Protein Assay Kit (Thermo Scientific) with bovine serum 
albumin as a standard, and equal amounts of protein (100 μg/lane) were fractionated on a 4–20% gradient gel 
(Bio-Rad).
Confocal Immunofluorescence Microscopy. For immunofluorescence analysis, intestines were washed 
with PBS and fixed in 4% (w/v) paraformaldehyde/PBS immediately following dissection. A 2-cm section of 
upper jejunum, positioned 1 cm from the stomach, was dissected and fixed with the same fixative solution over-
night at 4 °C with gentle shaking. Fixed tissue samples were processed and embedded into a paraffin block and 
sectioned at a thickness of 5 μm for immunofluorescence staining. The deparaffinized sections were heated at a 
sub-boiling temperature in 1 mM EDTA buffer (pH 8.0) for 15 min to expose the antigen. Samples were blocked 
with 2% (w/v) BSA and 0.2% Triton X-100 in PBS for 1 h and incubated with primary antibody (as described in 
the figure legends) for 1 h at room temperature. After washing with 0.2% BSA and 0.02% Triton X-100 in PBS, 
sections were incubated with Alexa Fluor 488 anti-rabbit IgG or Alexa Fluor 568 anti-mouse IgG (1:250 dilution 
in 1% (w/v) BSA in PBS) for 1 h at room temperature and washed with PBS. Then, the procedure of blocking 
and incubation with primary and secondary antibody was repeated as described above. Following incubation 
with Alexa Fluor 647 WGA-conjugate for 1 h at room temperature followed by washing, sections were mounted 
with Gold antifade reagent with DAPI, incubated overnight at 4 °C, and visualized with a Leica SP5 confocal 
microscope.
Reverse Transcription Quantitative PCR (RT-qPCR) Analysis. Total RNA was iso-
lated from intestinal epithelial cells or liver tissues by TRIzol reagent (Invitrogen). After eliminating 
genomic DNA using DNA-free DNA Removal Kit (Ambion), first strand cDNA was synthesized using 
SuperScript VILO Master Mix (Invitrogen). RT-qPCR was performed on an Agilent Mx3005P QPCR 
System Thermocycler (Agilent Genomics) using SYBR Green qPCR Master Mixes (Applied Biosystems). 
Levels of Atp7a, Ctr1, Mt1, and Mt2 mRNA were compared to an internal Gapdh control in mouse tis-
sues, and rat Atp7a transcript levels were compared to 18s rRNA control in IEC-6 cells..The fold change 
was determined using the 2(−ΔΔCt) method47. The oligonucleotide primer sequences used for PCR were: 
mAtp7a, 5′-ATGGAGCCAAGTGTGGATG-3′ and 5′-CCAAGGCAGAGTCAGTGGAG-3′; mGapdh, 
5′-ATGGTGAAGGTCGGTGTGAA-3′ and 5′-AGTGGAGTCATACTGGAACA-3′; mMT1, 5′-CACTTG 
CACCAGCTCCTG-3′ and 5′-GAAGACGCTGGGTTGGTC-3′; mMT2, 5′-CAAACCGATCTCTCGTCGAT-3′ 
and 5′- AGGAGCAGCAGCTTTTCTTG-3′; mCtr1, 5′-GGGCTTACCCTGTGAAGACTTTT-3′ and 
5′-AATGTTGTCGTCCGTGTGGT-3′ ; rat Atp7a, 5′-TGAACAGTCATCACCTTCATCGTC-3′  and 
5′-TGCATCTTGTTGGACTCCTGAAAG-3′; rat 18s rRNA, 5′-GCAATTATTCCCCATGAACG-3′ and 
5′-GGCCTCACTAAACCATCCAA-3′.
Tissue Metal Measurements. Cu and Fe concentrations were measured from nitric acid-digested cells or 
tissues by inductively coupled plasma mass spectrometry (ICP-MS) as described48. Tissues were collected into 
acid-washed 1.5-mL microcentrifuge tubes and weighed, and the harvested cultured cells were washed with PBS 
three times and weighed. The values were normalized by wet weight (g) of cells or mouse tissues. More extensive 
details can be found in previous reports48.
Statistics. Statistical significance was determined using a one-way or two-way ANOVA followed by Tukey’s 
post hoc test or two-tailed unpaired Student’s t-test in GraphPad Prism, Version 6 (GraphPad Software). All data 
are presented as mean ± SD, and P-values less than 0.05 were considered statistically significant.
www.nature.com/scientificreports/
1 2Scientific RepoRts | 7: 12001  | DOI:10.1038/s41598-017-11961-z
References
 1. van den Berghe, P. V. & Klomp, L. W. New developments in the regulation of intestinal copper absorption. Nutrition reviews 67, 
658–672, https://doi.org/10.1111/j.1753-4887.2009.00250.x (2009).
 2. Kim, B. E., Nevitt, T. & Thiele, D. J. Mechanisms for copper acquisition, distribution and regulation. Nature chemical biology 4, 
176–185, https://doi.org/10.1038/nchembio.72 (2008).
 3. Lutsenko, S. & Petris, M. J. Function and regulation of the mammalian copper-transporting ATPases: insights from biochemical and 
cell biological approaches. The Journal of membrane biology 191, 1–12, https://doi.org/10.1007/s00232-002-1040-6 (2003).
 4. Britton, R. S. Metal-induced hepatotoxicity. Seminars in liver disease 16, 3–12, https://doi.org/10.1055/s-2007-1007214 (1996).
 5. Halliwell, B. & Gutteridge, J. M. Oxygen toxicity, oxygen radicals, transition metals and disease. The Biochemical journal 219, 1–14 
(1984).
 6. Pena, M. M., Lee, J. & Thiele, D. J. A delicate balance: homeostatic control of copper uptake and distribution. The Journal of nutrition 
129, 1251–1260 (1999).
 7. Nevitt, T., Ohrvik, H. & Thiele, D. J. Charting the travels of copper in eukaryotes from yeast to mammals. Biochimica et biophysica 
acta 1823, 1580–1593, https://doi.org/10.1016/j.bbamcr.2012.02.011 (2012).
 8. Kuo, Y. M., Gybina, A. A., Pyatskowit, J. W., Gitschier, J. & Prohaska, J. R. Copper transport protein (Ctr1) levels in mice are tissue 
specific and dependent on copper status. The Journal of nutrition 136, 21–26 (2006).
 9. Nose, Y., Kim, B. E. & Thiele, D. J. Ctr1 drives intestinal copper absorption and is essential for growth, iron metabolism, and neonatal 
cardiac function. Cell metabolism 4, 235–244, https://doi.org/10.1016/j.cmet.2006.08.009 (2006).
 10. Ohrvik, H. & Thiele, D. J. How copper traverses cellular membranes through the mammalian copper transporter 1, Ctr1. Annals of 
the New York Academy of Sciences 1314, 32–41, https://doi.org/10.1111/nyas.12371 (2014).
 11. Nose, Y., Rees, E. M. & Thiele, D. J. Structure of the Ctr1 copper trans’PORE’ter reveals novel architecture. Trends Biochem Sci 31, 
604–607, https://doi.org/10.1016/j.tibs.2006.09.003 (2006).
 12. Linz, R. & Lutsenko, S. Copper-transporting ATPases ATP7A and ATP7B: cousins, not twins. Journal of bioenergetics and 
biomembranes 39, 403–407, https://doi.org/10.1007/s10863-007-9101-2 (2007).
 13. Madsen, E. & Gitlin, J. D. Copper and iron disorders of the brain. Annu Rev Neurosci 30, 317–337, https://doi.org/10.1146/annurev.
neuro.30.051606.094232 (2007).
 14. Kim, B. E., Smith, K. & Petris, M. J. A copper treatable Menkes disease mutation associated with defective trafficking of a functional 
Menkes copper ATPase. Journal of medical genetics 40, 290–295 (2003).
 15. Menkes, J. H., Alter, M., Steigleder, G. K., Weakley, D. R. & Sung, J. H. A sex-linked recessive disorder with retardation of growth, 
peculiar hair, and focal cerebral and cerebellar degeneration. Pediatrics 29, 764–779 (1962).
 16. Petris, M. J. et al. Ligand-regulated transport of the Menkes copper P-type ATPase efflux pump from the Golgi apparatus to the 
plasma membrane: a novel mechanism of regulated trafficking. The EMBO journal 15, 6084–6095 (1996).
 17. Petris, M. J., Strausak, D. & Mercer, J. F. The Menkes copper transporter is required for the activation of tyrosinase. Human molecular 
genetics 9, 2845–2851 (2000).
 18. Tchaparian, E. H., Uriu-Adams, J. Y., Keen, C. L., Mitchell, A. E. & Rucker, R. B. Lysyl oxidase and P-ATPase-7A expression during 
embryonic development in the rat. Archives of biochemistry and biophysics 379, 71–77, https://doi.org/10.1006/abbi.2000.1842 
(2000).
 19. Caruano-Yzermans, A. L., Bartnikas, T. B. & Gitlin, J. D. Mechanisms of the copper-dependent turnover of the copper chaperone for 
superoxide dismutase. The Journal of biological chemistry 281, 13581–13587, https://doi.org/10.1074/jbc.M601580200 (2006).
 20. Bertinato, J. & L’Abbe, M. R. Copper modulates the degradation of copper chaperone for Cu,Zn superoxide dismutase by the 26 S 
proteosome. The Journal of biological chemistry 278, 35071–35078, https://doi.org/10.1074/jbc.M302242200 (2003).
 21. Xie, L. & Collins, J. F. Copper stabilizes the Menkes copper-transporting ATPase (Atp7a) protein expressed in rat intestinal epithelial 
cells. American journal of physiology. Cell physiology 304, C257–262, https://doi.org/10.1152/ajpcell.00336.2012 (2013).
 22. Proceedings of a satellite meeting of the European Human Genetic Society on Copper Transport and Its Disorders: Molecular and 
Cellular Aspects. Sestri Levante, Italy, May 21–25, 1997. Advances in experimental medicine and biology 448, 1–269 (1999).
 23. Pyatskowit, J. W. & Prohaska, J. R. Copper deficient rats and mice both develop anemia but only rats have lower plasma and brain 
iron levels. Comparative biochemistry and physiology. Toxicology & pharmacology: CBP 147, 316–323, https://doi.org/10.1016/j.
cbpc.2007.11.008 (2008).
 24. Allen, K. J. et al. Chronological changes in tissue copper, zinc and iron in the toxic milk mouse and effects of copper loading. 
Biometals: an international journal on the role of metal ions in biology, biochemistry, and medicine 19, 555–564, https://doi.
org/10.1007/s10534-005-5918-5 (2006).
 25. Kim, B. E. et al. Cardiac copper deficiency activates a systemic signaling mechanism that communicates with the copper acquisition 
and storage organs. Cell metabolism 11, 353–363, https://doi.org/10.1016/j.cmet.2010.04.003 (2010).
 26. Lenartowicz, M. et al. Developmental changes in the expression of the Atp7a gene in the liver of mice during the postnatal period. 
Journal of experimental zoology. Part A, Ecological genetics and physiology 313, 209–217, https://doi.org/10.1002/jez.586 (2010).
 27. Lee, J., Petris, M. J. & Thiele, D. J. Characterization of mouse embryonic cells deficient in the ctr1 high affinity copper transporter. 
Identification of a Ctr1-independent copper transport system. The Journal of biological chemistry 277, 40253–40259, https://doi.
org/10.1074/jbc.M208002200 (2002).
 28. Pase, L., Voskoboinik, I., Greenough, M. & Camakaris, J. Copper stimulates trafficking of a distinct pool of the Menkes copper 
ATPase (ATP7A) to the plasma membrane and diverts it into a rapid recycling pool. Biochem J 378, 1031–1037, https://doi.
org/10.1042/BJ20031181 BJ20031181 [pii] (2004).
 29. Holloway, Z. G. et al. Activation of ADP-ribosylation factor regulates biogenesis of the ATP7A-containing trans-Golgi network 
compartment and its Cu-induced trafficking. American journal of physiology. Cell physiology 293, C1753–1767, https://doi.
org/10.1152/ajpcell.00253.2007 (2007).
 30. Abada, P. B., Larson, C. A., Manorek, G., Adams, P. & Howell, S. B. Sec. 61beta controls sensitivity to platinum-containing 
chemotherapeutic agents through modulation of the copper-transporting ATPase ATP7A. Molecular pharmacology 82, 510–520, 
https://doi.org/10.1124/mol.112.079822 (2012).
 31. Wake, S. A. & Mercer, J. F. Induction of metallothionein mRNA in rat liver and kidney after copper chloride injection. The 
Biochemical journal 228, 425–432 (1985).
 32. Petris, M. J., Smith, K., Lee, J. & Thiele, D. J. Copper-stimulated endocytosis and degradation of the human copper transporter, 
hCtr1. The Journal of biological chemistry 278, 9639–9646, https://doi.org/10.1074/jbc.M209455200 (2003).
 33. Nose, Y. et al. Ctr1 is an apical copper transporter in mammalian intestinal epithelial cells in vivo that is controlled at the level of 
protein stability. The Journal of biological chemistry 285, 32385–32392, https://doi.org/10.1074/jbc.M110.143826 (2010).
 34. Polishchuk, E. V. et al. Wilson disease protein ATP7B utilizes lysosomal exocytosis to maintain copper homeostasis. Dev Cell 29, 
686-700, doi:S1534-5807(14)00280-9 [pii]https://doi.org/10.1016/j.devcel.2014.04.033 (2014).
 35. Chen, H. et al. Decreased hephaestin activity in the intestine of copper-deficient mice causes systemic iron deficiency. The Journal of 
nutrition 136, 1236–1241 (2006).
 36. Nyasae, L., Bustos, R., Braiterman, L., Eipper, B. & Hubbard, A. Dynamics of endogenous ATP7A (Menkes protein) in intestinal 
epithelial cells: copper-dependent redistribution between two intracellular sites. American journal of physiology. Gastrointestinal and 
liver physiology 292, G1181–1194, https://doi.org/10.1152/ajpgi.00472.2006 (2007).
www.nature.com/scientificreports/
13Scientific RepoRts | 7: 12001  | DOI:10.1038/s41598-017-11961-z
 37. Lutsenko, S., Barnes, N. L., Bartee, M. Y. & Dmitriev, O. Y. Function and regulation of human copper-transporting ATPases. 
Physiological reviews 87, 1011–1046, https://doi.org/10.1152/physrev.00004.2006 (2007).
 38. La Fontaine, S. & Mercer, J. F. Trafficking of the copper-ATPases, ATP7A and ATP7B: role in copper homeostasis. Archives of 
biochemistry and biophysics 463, 149–167, https://doi.org/10.1016/j.abb.2007.04.021 (2007).
 39. Nittis, T. & Gitlin, J. D. Role of copper in the proteosome-mediated degradation of the multicopper oxidase hephaestin. The Journal 
of biological chemistry 279, 25696–25702, https://doi.org/10.1074/jbc.M401151200 (2004).
 40. Brady, G. F. et al. Regulation of the copper chaperone CCS by XIAP-mediated ubiquitination. Molecular and cellular biology 30, 
1923–1936, https://doi.org/10.1128/MCB.00900-09 (2010).
 41. Tao, T. Y. & Gitlin, J. D. Hepatic copper metabolism: insights from genetic disease. Hepatology 37, 1241–1247, https://doi.
org/10.1053/jhep.2003.50281 (2003).
 42. Maryon, E. B., Molloy, S. A. & Kaplan, J. H. O-linked glycosylation at threonine 27 protects the copper transporter hCTR1 from 
proteolytic cleavage in mammalian cells. The Journal of biological chemistry 282, 20376–20387, https://doi.org/10.1074/jbc.
M701806200 (2007).
 43. Ohrvik, H. et al. Ctr2 regulates biogenesis of a cleaved form of mammalian Ctr1 metal transporter lacking the copper- and cisplatin-
binding ecto-domain. Proceedings of the National Academy of Sciences of the United States of America 110, E4279–4288, https://doi.
org/10.1073/pnas.1311749110 (2013).
 44. Zimnicka, A. M., Ivy, K. & Kaplan, J. H. Acquisition of dietary copper: a role for anion transporters in intestinal apical copper 
uptake. American journal of physiology. Cell physiology 300, C588–599, https://doi.org/10.1152/ajpcell.00054.2010 (2011).
 45. Ouji, Y. et al. Isolation and characterization of murine hepatocytes following collagenase infusion into left ventricle of heart. Journal 
of bioscience and bioengineering 110, 487–490, https://doi.org/10.1016/j.jbiosc.2010.04.015 (2010).
 46. Chen, H. et al. Systemic regulation of Hephaestin and Ireg1 revealed in studies of genetic and nutritional iron deficiency. Blood 102, 
1893–1899, https://doi.org/10.1182/blood-2003-02-0347 (2003).
 47. Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta 
C(T)) Method. Methods 25, 402–408, https://doi.org/10.1006/meth.2001.1262 (2001).
 48. Lee, J., Prohaska, J. R. & Thiele, D. J. Essential role for mammalian copper transporter Ctr1 in copper homeostasis and embryonic 
development. Proceedings of the National Academy of Sciences of the United States of America 98, 6842–6847, https://doi.org/10.1073/
pnas.111058698 (2001).
Acknowledgements
We thank members of the Kim laboratory for helpful suggestions, technical assistance, and critical reading of this 
manuscript. We thank Dr. Michael J. Petris (University of Missouri-Columbia) and Dr. Stephen G. Kaler (NIH, 
Bethesda) for the anti-ATP7A antibody and Dr. Svetlana Lutsenko (Johns Hopkins University, Baltimore) for the 
anti-ATP7B antibody. This work was supported in part by the NIH (DK079209 to J.L.), and the Nebraska Redox 
Biology Center (P30GM103335).
Author Contributions
H.C. and B.-E.K. conceived the study. H.C. conducted the majority of the experiments, analyzed the data, and 
wrote most of the paper with B.-E.K. T.C. conducted Cu-administration experiments. H.J. and J.L. conducted 
ICP-MS analysis. All authors reviewed the results and approved the final version of the manuscript.
Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-017-11961-z.
Competing Interests: The authors declare that they have no competing interests.
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2017
